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ABSTRACT
The tumor suppressor, p53, is a transcription factor
which can modulate the transcription of a number
of target genes that are involved in cell-cycle arrest
and apoptosis. However, the apoptotic pathway
mediated by p53 is not fully understood. Here, we
showed that N-Myc downstream-regulated gene 2
(NDRG2) is a new target gene that is regulated
by p53. NDRG2 mRNA and protein levels can be
upregulated in a p53-dependent manner. The first
intron of the NDRG2 gene contains a site that binds
p53 directly and mediates wild-type p53-dependent
transactivation. In addition, silencing of NDRG2
attenuates p53-mediated apoptosis, whereas over-
expression of NDRG2 suppresses tumor cell growth,
regardless of the presence or absence of p53. Our
results indicate that NDRG2 is a novel p53-inducible
target that is involved in the p53-mediated apoptosis
pathway.
INTRODUCTION
The p53 tumor suppressor has long been regarded as the
most important factor for the maintenance of genome
integrity (1). In response to cellular stresses, p53 can
induce diverse biological responses, including cell-cycle
arrest, DNA repair and apoptosis (2). Though it is
widely accepted that apoptosis induction is essential to
the tumor-suppressive activity of p53 (3–5), the compli-
cated mechanism is not fully understood. Growing evi-
dence has shown that p53 can induce apoptosis through
its actions as a transcription factor by transactivating
numerous target genes in the apoptotic pathway (1,2,4).
Recently, reports have demonstrated that p53 exerts its
pro-apoptotic eﬀects through transcription-repressive
functions (6–9) as well as transcription-independent activ-
ities (10), suggesting that p53 may utilize multiple path-
ways to initiate apoptotic signals.
Under normal circumstances, p53 is maintained at low
levels mainly via the action of murine double minute 2
(MDM2) E3 ubiquitin ligase, which directs p53 ubiquiti-
nation and degradation. Upon various stresses, such as
hypoxia, heat shock, ionizing and UV light irradiation,
treatment with chemotherapeutic agents and viral infec-
tion, p53 protein levels rise dramatically and are activated
by posttranslational modiﬁcations to the protein itself
and/or MDM2 (2,11–13). Activated p53 functions as a
sequence-speciﬁc DNA-binding transcription factor and
induces expression of its downstream target genes by
recognizing a 20-bp response element, which is generally
located in the promoter or intronic regions. The consensus
sequence is 50-PuPuPuC(A/T-A/T)GPyPyPy-N(0–13)-
PuPuPuC(A/TA/T)GPyPyPy-30, and the fourth C and
seventh G are highly conserved in the 10-bp half-sites
(14). To date, more than a hundred p53 target genes
have been identiﬁed (10), and some of these proteins are
able to mediate p53-induced apoptosis. These proteins
include molecules with a pro-apoptotic potential, such as
BAX, NOXA, PUMA, BID, FAS/APO1, Pidd and
KILLER/DR5 (15–21), as well as some newly identiﬁed
proteins, which are not part of the canonical intrinsic
and extrinsic apoptotic pathways, such as Scotin,
voltage-gated sodium channel, type III, beta (SCN3B) and
N-Myc downstream-regulated gene 1 (NDRG1) (22–24).
Nevertheless, none of these downstream targets fully con-
tribute to the p53-mediated apoptotic response, indicating
that p53 may activate a subset of apoptosis-related genes
in a cell context- or stress type-dependent fashion (10,25).
Human NDRG2 (also named SYLD/KIAA1248)
belongs to the NDRG family and was ﬁrst cloned in our
laboratory from a normal human brain cDNA library by
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159092) (26). This family consists of four members,
NDRG1, NDRG2, NDRG3 and NDRG4, which share
roughly 60% residue identities (27–29). The members
have diﬀerent tissue expression patterns, indicating that
they may play distinct roles (27,28), but some exhibit simi-
larities in either expression regulation or biological func-
tions. For example, both NDRG1 and NDRG2 can be
transcriptionally repressed by Myc (30,31) and upregu-
lated by hypoxia and nickel reagent (32–34). Previous stu-
dies demonstrated that both proteins were involved in
cellular diﬀerentiation (35–38) and in certain human ner-
vous system disorders (39,40). Importantly, NDRG1 is
well-documented to be associated with a tumor-suppres-
sion function (37,41,42), and NDRG2 was proposed to be
a candidate tumor suppressor gene due to its reduced
expression in many cancer tissues and its ability to inhibit
proliferation in certain cancer cells (43–48). However, to
date, the exact function of Ndrg2 in cellular processes,
including carcinogenesis, is unclear. In a recent study,
Stein et al. (24) demonstrated that NDRG1 acts as a neces-
sary contributor during p53-induced caspase activation
and apoptosis. This led us to question whether there is a
relationship between NDRG2 and p53, which would help
identify the biological function of Ndrg2 and better under-
stand the p53-regulated cellular responses.
In this study, we report that the NDRG2 gene is tran-
scriptionally regulated by p53. NDRG2 mRNA and pro-
tein synthesis were induced by overexpressing p53 via
either an adenovirus infection or stabilization of p53
after DNA damage. Analysis of the NDRG2 genomic
loci revealed one potential p53-binding element in intron
1, which was veriﬁed as a functional p53 response element
that speciﬁcally binds to endogenous or exogenous p53. In
addition, our experiments using RNA interference suggest
that NDRG2 is involved in the p53-mediated apoptosis
pathway.
MATERIALS AND METHODS
Celllines and cell culture
The human tumor cell lines H1299 (p53 null), Saos2
(p53 null), MDA-MB-231 (mutant p53), SK-BR-3
(mutant p53), A549 [wild-type (wt) p53], U87 (wt p53)
and the human embryonic kidney cell line (HEK293)
were obtained from the American Type Culture
Collection (Manassas, VA, USA). Cells were maintained
in Dulbecco’s modiﬁed Eagle’s medium (Invitrogen Life
Technologies, Carlsbad, CA, USA), supplemented with
10% fetal bovine serum (FBS) (Sijiqing Biological
Engineering Materials Co., Hangzhou, China). Cells were
incubated at 378C in the presence of 5% CO2-balanced air.
Real-timePCR
Total RNA was extracted using TRIZOL reagent
(Invitrogen) according to the manufacturer’s protocol.
Total RNA (2mg) was reverse transcribed with
reverse transcriptase (Promega, WI, USA). The ﬁrst
strand cDNA was used as the template for real-time quan-
titative PCR analysis. b-Actin cDNA was used as an
internal control to normalize variances. The following
primers were designed using the ABI Primer Express
software for NDRG2: 50-GAGATATGCTCTTAACC
ACCCG-30 (forward) and 50-GCTGCCCAATCCATCC
AA-30 (reverse), for p21:5 0-GCACTGAATGCCAAG
GGAA-30 (forward) and 50-GCAATAACGGGAGGAG
CA-30 (reverse), and for b-actin:5 0-ATCATGTTTGA
GACCTTCAACA-30 (forward) and 50-CATCTCTTGCT
CGAAGTCCA-30 (reverse). NDRG2, p21 and b-actin
mRNAs were detected with SYBR Green PCR Master
Mix and an ABI PRISM 7500 Sequence Detection
System (Applied Biosystems, UK) using the comparative
threshold cycle (CT) method for relative quantiﬁcation.
The PCR reaction consisted of 12.5ml of SYBR Green
PCR Master Mix, 300nM of the forward and reverse
primers and 1.5ml template cDNA in a total volume of
25ml. The thermal cycling conditions were as following:
958C for 5min, followed by 45 cycles of 958C for 30s,
588C for 30s and 728C for 45s. To verify that the
primer pair produced a single product, a dissociation
protocol was used following thermocycling to determine
the dissociation of the PCR products from 658Ct o9 5 8C.
Western blot analysis
Cells were harvested from 60-mm culture dishes and were
lyzed in 200ml of RIPA buﬀer [0.05M Tris–HCl pH 7.4,
0.15M NaCl, 0.25% deoxycholic acid, 1% Nonidet P-40
(NP-40), 1mM EDTA, 1mM phenylmethylsulfonyl ﬂuor-
ide, 1mg/ml aprotinin and 1mg/ml leupeptin]. Protein con-
centrations were measured using the BCA protein assay
(Pierce, Rockford, IL, USA). Proteins were separated by
SDS–PAGE and transferred to Hybond-ECL nitrocellu-
lose membranes (Amersham Biosciences, Piscataway,
NJ, USA). Western blot analyses were carried out using
the following primary antibodies: anti-p53, anti-Ndrg2,
anti-p21 and anti-b-actin antibodies (Santa Cruz
Biotechnology, CA, USA), followed by incubation
in species-matched horseradish peroxidase (HRP)-
conjugated secondary antibodies. The blots were devel-
oped with chemiluminescence substrate solution (Pierce)
and exposed to X-ray ﬁlm.
Construction of reporter plasmids
A 24-bp fragment (50-CGCGTGTGCAAGGTCCGGG
GCGCTTGGCAA-30) that contains the potential p53-
binding sites (p53BSs) from NDRG2 intron 1 was syn-
thesized and cloned into the Mlu I and Bgl II sites of
the pGL3-promoter luciferase vector (pGL3-P-luc;
Promega). The pGL3-P-luc contains an SV-40 promoter
upstream of the luciferase reporter gene. The resulting
construct was named pGL3-p-NDRG2. A relative frag-
ment containing four nucleotides point mutations,
shown in lowercase (50-CGCGTGTGTAATGTCCGGG
GCGATTAGCAA-30), which are predicated to be critical
for p53 binding was also generated and cloned into the
reporter vector and named pGL3-p-NDRG2-m.
The 1379bp ( 56/+1323bp) and the 688bp ( 56/
+632bp) DNA fragments, which either contain or
delete the intronic p53BSs of the NDRG2 intron 1, respec-
tively, were ampliﬁed from the A549 genomic DNA
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p53BSs: 50-GCACGCGTGTTGGCCATCCTCTCCCCA
CC-30 (forward) and 50-GCAGATCTAGGGGGACTA
AACGCGGGGGAATA-30 (reverse), and for NDRG2-
p53BSs-del, 50-GCACGCGCTGTTGGCCATCCTCTC
CCCACC-30 (forward) and 50-GCAGATCTCCCGCAG
ACCCGCCCCAGACC-30 (reverse). These PCR products
were cloned into the Mlu I and Bgl II sites of the pGL3-
basic luciferase vector (pGL3-B-luc; Promega). The
corresponding constructs were named pGL3-B-NDRG2-
p53BSs and pGL3-B-NDRG2-p53BSs-del, respectively.
Transfection and reporter gene assay
Cells were seeded in a 24-well plate at a density of
1 10
5cells/well and transfected the next day using Lipo-
fectamine 2000 (Invitrogen Life Technologies), according
to the manufacturer’s protocol. Brieﬂy, for HEK 293 cells,
0.1mg of the reporter vector was cotransfected with 1mg
of the pcDNA3.1(+) control vector or a vector that
expresses wt or mutant p53. The Renilla luciferase vector
(0.01mg, pRL-CMV, Promega) was also cotransfected as
an internal control. Luciferase activity was measured 36h
after transfection using the dual-luciferase reporter assay
system. For A549, MDA-MB-231 and Saos2 cells, 1mg
of the reporter genes were cotransfected with 0.01mgo f
pRL-CMV. Then 12h after transfection, the cells were
treated with 0.4mg Adr for 24h and the luciferase activity
was measured.
Treatment of cells withsiRNA forp53 andNDRG2
The siRNA pSilencer
TM3.1-H1 neo vector system was uti-
lized and the siRNA motifs were selected from the human
p53 or NDRG2 cDNA sequence according to the AA-N19
rule (www.ambion.com/techlib/resources/RNAi). The
target sequence for p53 (NM_000546) is localized at posi-
tions 734-bp downstream from the start codon. The target
sequence for NDRG2 (AF159092) is localized at positions
604-bp downstream from the start codon.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) analysis
was performed using the ChIP Assay kit (Upstate
Biotechnology, Charlottesville, VA, USA). After infection
with Ad-p53 or Ad-LacZ for 48h, 2 10
6 Saos2 cells were
cross-linked with 1% formaldehyde for 10min at 378C.
After treatment with 0.4mg Adr or DMSO for 24h,
6 10
6 A549 cells were cross-linked with 1% formalde-
hyde for 10min at 378C. The cells were then washed,
lyzed and sonicated to generate 200–500bp DNA frag-
ments. The samples were precleared with 60ml of salmon
sperm DNA–protein A-agarose and subsequently incu-
bated at 48C overnight with 5mg anti-p53 antibody
(Santa Cruz Biotechnology, CA, USA), with mIgG and
no antibody serving as control. Immunocomplexes were
recovered, washed thoroughly and eluted with the ChIP
elution buﬀer. Following the reversal of cross-links at
658C for 4h, samples were extracted with phenol/chloro-
form, precipitated with ethanol and then used as templates
for PCR ampliﬁcation, using primers ﬂanking the p53BSs
in the NDRG2 intron 1 or the control region. For NDRG2
p53BSs, forward primer 50-CAAAGGCTGAGGCTCCA
AGAG-30 (+889/+910bp), reverse primer 50-TCGGGA
AGGGATGGGTAGG-30 (+1063/+1082bp). For the
NDRG2 negative control, forward primer 50-GTTAGCG
GCGAAGCCACAGG-30 ( 235/ 215bp), reverse primer
50-TGGGGTCAATGCCTCAAGGG-30 ( 82/ 62bp).
The PCR products generated from the ChIP assay were
sequenced to verify the identity of the ampliﬁed DNA.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was per-
formed according to the EMSA kit procedure (Pierce).
Nuclear extracts were prepared from A549 cells treated
with or without Adr or from Saos2 cells infected with
Ad-p53 or Ad-LacZ. Then endogenous or exogenous
p53 protein was prepared using the NE-PER nuclear
and cytoplasmic extraction reagents. Brieﬂy, cells
(1 10
7) were resuspended in 200ml cytoplasmic extrac-
tion reagent (CER) I containing protease inhibitors, incu-
bated on ice for 10min and then 11ml of CER II was
added and incubated for 1min on ice. After centrifugation
at 12000r.p.m. for 10min, the cell pellets were resus-
pended in 50ml nuclear extraction reagent (NER) contain-
ing protease inhibitors and rotated at 48C for 1h.
Supernatants with nuclear proteins were recovered by cen-
trifugation at 12000r.p.m. for 15min. The candidate
p53BSs in the NDRG2 intron 1 and the corresponding
complementary sequence (50-TGTGTGCAAGGTCCGG
GGCGCTTGGCACCG-30) were prepared as probes,
named NDRG2-wt-p53BSs. A mutant version (50-TGTG
TGTAATGTCCGGGGCGATTAGCACCG-30) was also
prepared and named NDRG2-mt-p53BSs. A 50-biotin
modiﬁcation was included in all probes except for the
competitor oligonucleotides, which did not contain any
modiﬁcations. Nuclear proteins (3mg) were incubated
with 10 fmol of biotin-labeled NDRG2-wt-p53BSs or
NDRG2-mt-p53BSs, and the DNA–protein complexes
were separated on a 6% nondenaturing polyacrylamide
gel in 0.5 TBE with 2.5% glycerol and transferred to
positively charged nylon membranes. The membranes
were blocked with blocking buﬀer and incubated with
HRP-conjugated streptavidin. The blots were developed
with chemiluminescence substrate solution (Pierce) and
exposed to X-ray ﬁlm. For competition assays, 100- or
200-fold excess of unlabeled probes were added to the
reaction mixture for 1h at room temperature before the
addition of the labeled probe.
Adenovirusinfection
Adenoviruses carrying wt-p53 (Ad-p53) or the negative
control Lac Z (Ad-lac Z) were purchased from Benyuan
Zhengyang Company (Beijing, China). The multiplicity of
infection (MOI) was determined for the Saos2 and H1299
cell lines.
Gene transfection
All transfections were performed with lipofectamine
2000 (Invitrogen Life Technologies), according to the
manufacturer’s instructions. For stable transfection,
single colonies were obtained after selection with G418
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clones were analyzed using western blot analysis.
MTTassay
The cells were seeded into 96-well plates at a starting den-
sity of 1 10
3cells/well in triplicate. At each time point,
the cells were washed and incubated with tetrazolium salt
(MTT, 100mg/ml, Sigma) at 378C for 4h. The supernatant
was removed, and 150ml DMSO was added to each well.
The absorbance (OD) of the reaction solution at 570nm
was recorded. Each experiment was performed in tripli-
cate, and the values were reported as the mean SD.
Colonyformation assay
Saos2 cells, which were stably transfected with either the
empty vector [pcDNA3.1(+)] or the vector carrying Flag-
tagged NDRG2 [pcDNA3.1(+)-F-2 and pCDNA 3.1(+)-
F-4], were seeded into 6-cm dishes at a density of 200 cells/
dish. The cells were grown for 4 weeks in selective cultur-
ing medium (G418, 500mg/ml). Then, the colonies were
ﬁxed and stained with Coomassie blue.
Detectionof apoptosis
Apoptosis was detected using ﬂow cytometry analysis and
the terminal uridine deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL) assay. For ﬂow cytometry,
cells were harvested following mild trypsinization and
were washed with phosphate-buﬀered saline (PBS). Cell
death was measured using two-color analysis of ﬂuores-
cein isothiocyanate-labeled annexin V (Roche Applied
Science) binding and propidium iodide (PI) uptake using
a Becton Dickinson ﬂuorescence-activated cell sorter
(FACS) apparatus. For the TUNEL assay, the Apoptag
Direct in situ Apoptosis Detection Kit-Fluoresence
(Roche Applied Science, Basel, Switzerland) were used
to detect DNA fragmentation in apoptotic cells by direct
end-labeling of cellular genomic DNA with a ﬂuorescein-
conjugated nucleotide using the terminal deoxynucleoti-
dyltransferase enzyme. Cells were washed, ﬁxed in 4%
formaldehyde in PBS for 30min at room temperature
and stored dry on aminoalkylsilane-coated slides at
 208C before processing. 40,6-Diamidino-2-phenylindole
(DAPI) was used for counterstaining. The cells ﬁxed on
slides were observed using a ﬂuorescence microscope.
Statistical analysis
Data are expressed as the mean SD. Statistical analyses
were performed with the SPSS software (version 10.0;
SPSS, Chicago, IL, USA) by using the t-test for indepen-
dent groups. Statistical signiﬁcance was based on a value
of P<0.05.
RESULTS
Induction ofNDRG2 by DNA-damaging agents or stress
isp53 dependent
Adr, as a topoisomerase II inhibitor, is able to induce
double-strand DNA breaks, and consequently stabilize
and activate p53, which results in the induction of p53
target genes (13,49). To explore the relationship
between NDRG2 and p53, we ﬁrst examined the changes
of NDRG2 mRNA and protein levels in response to p53
activation by Adr. Adr treatment resulted in increased
expression of NDRG2 and p21 in both A549 and U87
cells as measured by real-time PCR (Figure 1A). The
increase in NDRG2 mRNA began after 3h and was
signiﬁcant 6h following Adr treatment. Additionally,
Ndrg2 protein expression increased in A549 cells as
detected by western blot (Figure 1B). Two other classical
p53 inducible treatment (MMS and UV) can also upregu-
late the expression of NDRG2 in mRNA and protein level
(Figure 1C and D). In contrast, the eﬀect of Adr on
NDRG2 expression was not observed in either the
mutant p53-bearing cell lines, including MDA-MB-231
and SK-BR-3, or the H1299 p53 null cell line (Figure 1E
and F). To further conﬁrm that upregulation of Ndrg2
is p53-dependent, we transfected A549 cells with
pSilencer3.1-p53 to knockdown endogenous p53, treated
them with Adr and then observed the change of Ndrg2
protein level. As shown in Figure 1G, reduction of endo-
genous p53 markedly attenuated Adr-induced increase of
Ndrg2 (Figure 1G). These data strongly suggest that the
elevated expression of NDRG2 by DNA-damaging agents
or stress is p53 dependent.
Ectopic expression of p53 results in upregulationof NDRG2
To directly investigate whether p53 can upregulate
NDRG2 expression, we examined the eﬀect of exogenously
introduced p53 via either adenoviral infection or gene
transfection on the expression of NDRG2 in p53 null
H1299 cells. We found that the Ndrg2 protein level was
upregulated due to the increase in exogenous p53 follow-
ing adenovirus infection, similar to p21, which is a known
p53 target gene (Figure 2A and B). We also detected that
the NDRG2 mRNA level increased with p53 overexpres-
sion (Figure 2C), suggesting that the eﬀect occurred at the
transcriptional level. Meanwhile, transfection of only the
wt p53, but not the mutant forms (175H and 248W),
upregulated the expression of NDRG2 (Figure 2D), indi-
cating that NDRG2 may be a p53 target gene.
The putative p53-binding site in NDRG2 intron 1
is responsive top53
It is well known that the upstream regulatory regions and
intronic regions of p53-regulated genes may contain
p53BSs (50). By analyzing the genomic sequence of
NDRG2, we identiﬁed a putative sequence for p53BSs in
intron 1 (50–G TGCAAGGTCCGGGGCGCTTGGCA-30)
(Figure 3A). The sequence contains mismatches (shown
in lower case) in the nonconserved positions within the
consensus p53BS.
To determine whether the putative binding site in
NDRG2 was responsive to p53, a fragment containing
this element was synthesized and cloned into a pGL3-
promoter luciferase vector (pGL3-p-NDRG2). A mutant
reporter vector, pGL3-p-NDRG2-m, was also generated by
replacing the four nucleotides in the p53BSs (see Materials
and methods section). The empty reporter vector, pGL3-p,
served as the control (Figure 3A). Each reporter vector
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pcDNA3.1(+) control vector or a vector expressing
wt p53 or mutant p53 (R175H). We found that the wt
p53 was capable of increasing the luciferase activity of
pGL3-p-NDRG2 markedly, while the mutant p53 and
empty vector did not. The luciferase activity was nearly 4-
fold higher after transfection with pGL3-p-NDRG2
than after transfection with the control vector. When the
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Figure 1. Induction of NDRG2 by DNA-damaging reagents or stress depends on the presence of wt p53. (A) The levels of the NDRG2 and p21
transcripts were assessed by real-time PCR assays in A549 cells and U87 cells that were treated with Adr (0.2mg/ml) for 0, 3, 6, 12 and 24h. (B) The
levels of the p53, Ndrg2 and p21 proteins were assessed by western blot in A549 cells that were treated with 0.2mg/ml Adr for 0, 3, 6, 12 and 24h.
(C) The levels of the NDRG2 and p21 transcripts were assessed by real-time PCR assays in A549 cells that were treated with methyl methanesulfo-
nate (MMS, 120mg/ml) or irradiated with UV (7.5J/m
2) for 0, 3, 6, 12 and 24h. (D) The levels of the Ndrg2 and p21 proteins were assessed by
western blot in A549 cells that were treated with MMS (120mg/ml) or irradiated with UV (7.5J/m
2) for 0, 3, 6, 12 and 24h. (E) The levels of the p53,
Ndrg2 and p21 proteins were assessed by western blot in MDA-MB-231 and SKBR-3 cells that were treated with or without 0.2mg/ml Adr for 24h.
(F) The levels of the NDRG2 transcripts were measured by real-time PCR assays in H1299 cells that were treated with 0.2mg/ml Adr for 0, 3, 6, 12
and 24h. (G) A549 cells were transiently transfected with pSilencer3.1-p53 or pSilencer3.1-X and 24h later, cells were treated with or without
0.2mg/ml Adr for 24h. The levels of the p53 and Ndrg2 proteins were assessed by western blot. In (B), (D), (E) and (G), actin was used as a loading
control. The experimental details are described in the Materials and methods section.
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transactivation was signiﬁcantly diminished (Figure 3B),
implying that the p53BSs in intron 1 of NDRG2 are
required for responsiveness to exogenous p53.
We then examined the eﬀect of activation of endogen-
ous p53 via Adr treatment on the transactivation of the
reporter vectors. We found that the luciferase activity of
pGL3-p-NDRG2, rather than pGL3-p-NDRG2-m or
pGL3-p, was markedly increased in wt p53-bearing
A549 cells after treatment with 0.2mg or 0.4mg Adr
(Figure 3C). In contrast, Adr treatment failed to increase
the transcriptional activity of pGL3-p-NDRG2 in either
mutant p53-bearing MDA-MB-231 cells or p53 null
Saos2 cells (Figure 3D). Together, these results indicated
that the p53BSs in the NDRG2 intron 1 is responsible for
mediating p53-induced gene transactivation.
Next, we examined whether the intronic p53BSs in
NDRG2 are required for driving p53-induced trans-
activation of its own promoter. We ampliﬁed the DNA
fragments consisting of the NDRG2 promoter, exon 1 and
intron 1 containing p53BSs and its corresponding mutant
counterpart that lacked p53BSs, cloned them into pGL3-
B-luc, and named the vectors pGL3-B-NDRG2-p53BS and
pGL3-B-NDRG2-p53BS-del, respectively (Figure 3A).
The pGL3-B vector served as the control. When each
of these reporter vectors was cotransfected into HEK293
cells with either the pcDNA3.1(+) control vector or vec-
tors expressing the wt p53 or mutant p53 (R175H),
we observed that the luciferase activity of pGL3-B-
NDRG2-p53BSs could be induced only by wt p53, and
not by the mutant p53 or empty vector. Moreover, neither
the wt nor the mutant p53 was capable of increasing the
transcriptional activity of pGL3-B-NDRG2-p53BSs-del
(Figure 3E), which strongly suggests that the intronic
p53BSs are indispensable for p53-mediated transactivation
of NDRG2.
p53bindsdirectlytothep53-bindingsitesinNDRG2intron1
To further verify that NDRG2 is a p53 target gene, ChIP
and EMSA were performed to examine whether p53
directly binds to the p53BSs in intron 1 of NDRG2.
First, we demonstrated that both exogenous and endogen-
ous p53 can bind the p53BSs in intron 1 of NDRG2 using
the in vivo ChIP assay. As shown in Figure 4A, in Saos2
cells upon Ad-p53 infection and in A549 cells upon Adr
treatment, the fragment (+889/+1082bp) containing the
p53BSs in NDRG2 intron 1 was ampliﬁed by PCR from
DNA–protein complexes that were coimmunoprecipitated
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5340 Nucleic Acids Research, 2008, Vol. 36, No. 16using the anti-p53 antibody. In contrast, a DNA sequence
( 235/ 62bp) far from the p53BSs failed to be coimmu-
noprecipitated and ampliﬁed.
Next, we used EMSA to conﬁrm this interaction
in vitro. As shown in Figure 4B and C, when the labeled
wt probe for NDRG2-p53BSs was incubated with extracts
from Ad-p53-infected Saos2 cells or Adr-treated A549
cells, we detected a clear band shift that did not occur
with Ad-LacZ infection (Figure 4B, lane 4 versus 9)
or vehicle treatment (Figure 4C, lane 4 versus 9).
However, when using the mutant NDRG2-p53BSs probe,
we did not observe band shifts with extracts from either
Ad-p53-infected Saos2 cells (Figure 4B, lane 2) or Adr-
treated A549 cells (Figure 4C, lane 2). The unlabeled wt
NDRG2-p53BSs probe, rather than the mutant version,
is able to reduce the protein–DNA complex formation in
a dose-dependent manner when included in the reaction as
a competitor (Figure 4B and C, lane 4 versus lanes 5 and
6; and lane 7 versus 8). Taken together, these results indi-
cate that NDRG2 is a direct target gene of p53.
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Figure 2. Exogenous, overexpressed p53 induces upregulation of NDRG2.(A) The levels of the p53,Ndrg2 and p21 proteins were assessed bywestern blot
in H1299 cells that were infected with Ad-LacZ or diﬀerent MOI Ad-p53 for 48h. (B) The levels of the p53, Ndrg2 and p21 proteins were assessed by
western blot in H1299 cells that were infected with 40 MOI Ad-p53 for 0, 24, 48 and 72h. (C) The levels of the NDRG2 transcripts were measured by real-
time PCR assays in H1299 cells that were infected with Ad-LacZ for 24h or with 40 MOI Ad-p53 for 0, 3, 6, 12, 24 and 48h. (D) H1299 cells were
transfected with pcDNA3.1(+), pcDNA3.1(+)-wt-p53, pcDNA3.1(+)-175H or pcDNA3.1(+)-248W, respectively. Twenty-four hours after transfec-
tion, the protein levels of p53, Ndrg2 and p21 were determined by western blot. In (A), (B) and (D), actin was used as a loading control.
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Figure 3. The putative p53-binding site in intron 1 of NDRG2 is responsive to p53 and is required for p53-dependent transactivation of NDRG2
promoter. (A) Shown are the wt putative p53-binding site located within NDRG2 intron 1, its corresponding mutant version and a schematic diagram
of the various reporter vectors used in the luciferase assays. (B) Activation of the p53-binding site in NDRG2 intron 1 by exogenous wt p53. HEK293
cells were individually cotransfected with an equal amount (0.1mg) of reporter vectors (pGL3-p, pGL3-p-NDRG2 or pGL3-p-NDRG2-m) and either
empty vector pcDNA3.1(+) or a vector expressing wt p53 [pcDNA3.1(+)-wt-p53] or mutant p53 [pcDNA3.1(+)-175H]. Luciferase activity was
determined 36h following transfection. (C) Activation of the p53-binding site in NDRG2 intron 1 by endogenous p53 in response to DNA damage in
A549 cells. A549 cells were transfected with pGL3-p, pGL3-p-NDRG2 or pGL3-p-NDRG2-m, and 12h later, the cells were treated with the indicated
amount of Adr for 24h, and luciferase activity was determined. (D) Responsiveness of the p53-binding site in NDRG2 intron 1 to endogenous p53
depends on the presence of wt p53. A549, MDA-MB-231 or Saos2 cells were individually transfected with pGL3-p-NDRG2, 12h later, cells were
treated with the indicated amount of Adr for 24h, and then luciferase activity was determined. (E) The reporter vectors (pGL3-B, pGL3-B-NDRG2-
P53BSs or pGL3-B-NDRG2-P53BSs-del) were cotransfected into HEK293 cells with either pcDNA3.1(+) or a vector expressing wt p53
[pcDNA3.1(+)-wt-p53] or mutant p53 [pcDNA3.1(+)-175H], and 36h later, luciferase activity was determined. In (B–D), Renilla luciferase
vector pRL-CMV was also cotransfected as an internal control vector. Luciferase and Renilla activity was assayed using the Dual-Luciferase
Reporter Assay System (Promega), and luciferase fold activation values were measured relative to the levels of Renilla activity. The histograms
represent the average of three independent experiments with error bars showing the SD.
 P<0.05 among each compared group.
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Figure 4. p53 binds to the putative p53-binding site of NDRG2 intron 1 in vivo and in vitro.( A) Binding of exogenous or endogenous p53 to the p53-
binding site in NDRG2 intron 1 in vivo by the ChIP assay. Cell lysates from Saos2 cells that were infected with Ad-p53 or Ad-LacZ for 48h (left,
upper and lower panel) or from A549 cells that were pretreated with 0.4 mg/ml Adr or DMSO for 24h (right, upper and lower panel) were prepared,
cross-linked and immunoprecipitated in the presence or absence of p53-speciﬁc antibody. The immunoprecipitated samples were analyzed by PCR
ampliﬁcation using the primers ﬂanking the p53BSs in NDRG2 intron 1 or the control region, as indicated in the Materials and methods section.
Genomic DNA and input chromatin (input), which represent portions of sonicated chromatin before immunoprecipitation, were both used as
positive controls. (B and C) Binding of exogenous or endogenous p53 to the p53-binding site in NDRG2 intron 1 in vitro was measured by
EMSA. Nuclear extracts of Saos2 cells that were infected with Ad-p53 or Ad-LacZ for 48h (B) or of A549 cells that were pretreated with or
without Adr for 24h (C) were prepared and incubated with biotin-labeled wt or mutant probes for p53BSs in NDRG2 intron 1 [NDRG2-wt-p53BSs
(lanes 3–9); NDRG2-mt-p53BSs (lanes 1 and 2)], or together with competitive unlabeled probes [NDRG2-wt-p53BSs (lanes 5 and 6); NDRG2-mt-
p53BSs (lane 8)]. DNA–protein complexes were separated on a 6% TBE gel, transferred to nylon membranes and shifted probes were detected with
HRP-conjugated streptavidin.
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To investigate the functional role of Ndrg2 in the p53-regu-
lated pathway, Saos2 (p53 null) cells and A549 (wt-p53)
were transfected with siRNA vectors that target NDRG2
(pSliencer-NDRG2) or control vectors (pSliencer-X) and
stable cell clones were obtained. As shown in Figure 5A
(left panel), the expression of Ndrg2 was ampliﬁed after
p53 introduction (Saos2) or Adr treatment (A549) in the
control cells, whereas such aneﬀect was obviously compro-
mised in the NDRG2-siRNA transfectants.
To determine whether Ndrg2 contributed to p53-
mediated apoptosis, we ﬁrst examined the pro-apoptotic
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Figure 5. Silencing of NDRG2 attenuates p53-mediated apoptosis. Saos2 and A549 cells were transfected with pSilencer-X or pSilencer-NDRG2 and
stable clones were generated. Stable clones were either infected with Ad-p53 or Ad-LacZ (mock) for 48h (Saos2) or treated with 0.4 mg/ml Adr or
DMSO (mock) for 24h (A549). (A) Western blot was performed using anti-Ndrg2, anti-p53 and anti-actin antibodies, respectively. (B and C) The
apoptotic cells were analyzed by ﬂow cytometry and quantiﬁed (B) or analyzed by the TUNEL assay (C). All the experiments were independently
performed in triplicate. In (B), the histograms represent the average with error bars showing the SD.
 P<0.05.
5344 Nucleic Acids Research, 2008, Vol. 36, No. 16eﬀect of p53 introduction in Saos2 cells, where NDRG2
expression was either knocked down or not. As shown
in upper panel of Figure 5B, control cells transfected
with pSilencer-X underwent extensive p53-triggered apo-
ptosis, as indicated by the proportion of annexin V posi-
tive cells (74.8%). In contrast, the p53-inducecd apoptotic
eﬀects were greatly compromised by NDRG2 knockdown
in pSilencer-NDRG2 transfected cells (44.2%). Next, we
observed whether Ndrg2 knockdown also had an eﬀect on
the process of endogenous p53-mediated apoptosis in
A549 cells that were treated with Adr. As shown in
lower panel of Figure 5B, Adr treatment caused more
apoptosis in the cells transfected with pSilencer-X than
pSilencer-NDRG2 (72.1+5.3% versus 65.1+2.1%,
P<0.01). Finally, we conﬁrmed these results by the
TUNEL assay. As shown in Figure 5C, there are signiﬁ-
cantly more apoptotic cells in the pSilencer-X transfec-
tants than in the pSilencer-NDRG2 transfectants
following Ad-p53 infection in Saos2 cells/or Adr treat-
ment in A549 cells. These data indicate that Ndrg2 is
required for p53-mediated apoptosis.
Overexpression of NDRG2 suppresses tumorcell growth
To further evaluate the biological role of Ndrg2 in tumor
cells, we generated two Saos2 cell lines that were
stably transfected with pcDNA3.1(+)-Flag-NDRG2
[pcDNA3.1(+)-F-2 and pcDNA3.1(+)-F-4], and stable
empty vector-transfected clones [pcDNA3.1(+)] were
used as the control. Ndrg2 overexpression was conﬁrmed
by western blot analysis (Figure 6A).
To determine whether Ndrg2 has any eﬀect on cell
growth, we performed the MTT assay (Figure 6B). The
results demonstrated that enhanced expression of Ndrg2
inhibited cell growth in comparison to the control, imply-
ing that Ndrg2 may play an inhibitory role in cell prolif-
eration. We then performed colony formation assays to
evaluate the proliferating ability of these cells. As shown
in Figure 6C, overexpressed Ndrg2 signiﬁcantly inhibited
the colony-forming ability of Saos2 cells, consistent with
the results of the MTT assay.
Considering that stable clones generated by selective
pressure may diﬀer from their parental cells, we also
transiently transfected pcDNA3.1(+)-Flag-NDRG2 into
Saos2 cells and observe its eﬀect on cell growth and
apoptosis. The results showed that enhanced expression
of Ndrg2 inhibits cell growth in comparison to the control
(Figure S1B). However, Ndrg2 overexpression does not
promote cell apoptosis (Figure S1C), implying that
Ndrg2 suppresses cell growth through inhibiting prolifer-
ation rather than inducing apoptosis.
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Figure 5. Continued.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5345To further examine whether Ndrg2 has an antiprolifera-
tion eﬀect on wt p53-bearing tumor cells, we infected A549
cells with Ad-NDRG2 or Ad-LacZ and found that Ndrg2
overexpression suppressed the growth of A549 cells using
the MTT assay (data not shown). Collectively, these data
suggest that Ndrg2 is involved in suppression of cell pro-
liferation, regardless of the presence or absence of p53.
DISCUSSION
As one of the most commonly altered genes in human
cancer, research on p53 has been intense for many years.
It is well established that most of the biological eﬀects of
p53 are due to its function as a transcription factor.
Although a variety of p53 downstream target genes have
been identiﬁed, which are involved in apoptosis (e.g. BAX,
DR5, BID, APAF-1, Caspase-6, PIGs, Perp, p53AIP,
SCN3B and Scotin), knockout of any one individual
gene has failed to protect cells completely from p53-
induced death. These ﬁndings suggest that the p53
response requires a network of collaborating genes
(10,13,17,19,21–23,25,50–54). In addition, several studies
have shown that some genes with antiapoptotic activity,
such as HB-EGF, DcR1 and DcR2, can be transcription-
ally activated by p53 (55–57), while others, such as survi-
vin and PTGG1, are repressed by p53 (6,7). Thus, the p53
pathway is complicated, and identiﬁcation of additional
p53 targets is critical for understanding the pathway.
Here, our results reveal that NDRG2 is a p53-inducible
target gene that is transactivated by p53 and is involved
in p53-mediated apoptosis.
Increased NDRG2 mRNA and protein levels occurred
not only after treatment with the DNA-damaging
agents or stress, which activates endogenous p53, but
also following adenovirus-mediated ectopic expression of
p53 in p53 null cells. Neither DNA damage in p53 mutant
and p53 null cell lines nor introduction of mutant
p53 could enhance NDRG2 expression; moreover, knock-
down of endogenous p53 markedly attenuated Adr-
induced increase of Ndrg2, indicating that the eﬀect
requires intact p53. Considering the previous ﬁnding
that NDRG1, a member of NDRG family, is a direct tran-
scriptional target gene of p53, we hypothesized that
NDRG2 could also be a p53 target gene.
While NDRG1 has a p53 responsive element in its pro-
moter, we identiﬁed one candidate sequence for p53BSs
within intron 1 of NDRG2. The NDRG2 element con-
tained all the conserved residues, as well as ﬁve mis-
matches, of the consensus p53BS. It is well documented
that p53 target genes harbor p53BSs in either their pro-
moters or intronic regions, and sequences with diﬀerent
mismatched bases may vary considerably in their transac-
tivation function (52,58). Interestingly, some response
elements whose structures are quite diﬀerent from the
canonical p53 consensus site can also be recognized by
p53 (52).
Our experiments demonstrate that the putative p53BS
within NDRG2 intron is a functional one in response to
exogenous or endogenous wt p53, as shown in reporter
assays. Reporter constructs carrying the endogenous
NDRG2 promoter region, exon 1 and intron 1 containing
p53BSs exhibited increased transcriptional activity upon
p53 activation. Meanwhile, the corresponding counterpart
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Figure 6. Overexpression of NDRG2 inhibits cell growth in Saos2 cells. (A) Saos2 cells were transfected with either empty vector [pcDNA3.1(+)] or
the vector carrying Flag-tagged NDRG2 and stable clones were generated. Western blot was performed using anti-Ndrg2, anti-Flag and anti-actin
antibodies, respectively. pcDNA3.1(+)-F-2 and pcDNA3.1(+)-F-4 represent the two diﬀerent clones that overexpress Ndrg2. (B) The stable Saos2
clones indicated in (A) were seeded into 96-well plates at a starting density of 1 10
3 cells/well in triplicate, and growth curves were obtained by the
MTT assay. (C) The stable Saos2 clones indicated in (A) were seeded into 6-cm dishes at a density of 200 cells/dish in triplicate and cultured in the
presence of G418 (500mg/ml) for four weeks to allow colonies to develop. The colonies were ﬁxed, stained with Coomassie blue and photographed
(the representative dishes are shown).
5346 Nucleic Acids Research, 2008, Vol. 36, No. 16lacking p53BSs showed no response to p53, indicating that
the intronic p53BSs are essential for p53-mediated trans-
activation of NDRG2. Using ChIP and EMSA, we demon-
strated that the p53BSs form protein–DNA complexes
in Ad-p53-infected p53 null cells or Adr-treated wt p53-
bearing cells, suggesting that the intronic NDRG2 p53BSs
can bind to p53 after its activation and DNA damage.
Collectively, we provide compelling evidence that p53
directly transactivates NDGR2 via intronic p53BSs.
As a member of the NDRG family, the NDRG2 gene has
been mapped to chromosome 14q11.2, and encodes a
41kDa protein, which is expressed in various tissues,
particularly in the brain, heart and skeletal muscle (28).
Although the precise function of Ndrg2 is still unclear,
it has been shown to be intimately involved in numerous
biological processes, such as cell diﬀerentiation (30,35,38),
neurodegeneration (39), stress responses (34), as well
as carcinogenesis and cancer progression (44,46–48).
Mounting evidence has indicated that NDRG2 mRNA
levels are downregulated or undetectable in a number of
human cancers and cancer cell-lines, including glioblas-
toma, squamous cell carcinoma, pancreatic cancer, gastric
cancer and colorectal carcinoma, compared to their cog-
nate noncancerous counterparts (44,46–48). Moreover,
NDRG2 expression has been inversely correlated with
tumor grade and aggressive tumor behavior (43,45). In
two recent reports, NDRG2 was even identiﬁed as a gene
whose expression in high-grade primary astrocytomas or
gastric cancers was positively correlated with survival
(47,48). These ﬁndings strongly implicate Ndrg2 is a
tumor suppressor. However, to date, only a few studies
have explored the role of Ndrg2 in tumor suppression.
Ndrg2 overexpression in a human glioblastoma cell line
was shown to markedly inhibit cell proliferation (43).
Another study from our laboratory demonstrated that
Ndrg2 translocates from the cytosol into the nucleus
upon NiCl2 treatment, where it interacts with the
MSP58 oncoprotein and inhibits MSP58-induced prolif-
eration of HeLa cells (59). Most recently, Choi et al. (47)
demonstrated that NDRG2 silencing can decrease Fas-
mediated cell death via a slight downregulation of Fas
expression in SNU-620 gastric cancer cell lines.
Here, we showed that Ndrg2 is required for the full p53-
mediated apoptotic response. Additionally, we showed
that NDRG2 knockdown using siRNA markedly attenu-
ated the p53-mediated apoptotic eﬀect. It is possible that
the attenuation was incomplete because the silencing eﬃ-
ciency in our current experiment was not high enough to
entirely block the NDRG2 expression. Alternatively, it is
likely that other apoptosis-related proteins that are down-
stream of p53 play a compensatory role in the case of
NDRG2 knockdown by contributing to the apoptotic
eﬀect. In this regard, the function of Ndrg2 may be similar
to many known p53 targets, such as BAX, BID, CD95,
APAF-1 and DR5, since when each of these genes
is silenced or removed from a particular model system,
a partial resistance to p53-induced apoptosis is observed
(17–19,21,25,54). Therefore, our results together with two
recent reports (23,34) support the idea that p53-dependent
apoptosis is a complex process, reﬂecting the combined
eﬀect of a number of p53-inducible targets. As for the
role of Ndrg2 in the p53-initiated apoptosis pathway, it
is unlikely that Ndrg2 functions as a pro-apoptotic factor
because we did not observed Ndrg2-promoted apoptosis
following its overexpression in p53-null Saos2 cells
and p53-intact A549 cells (34). Another possibility is
that Ndrg2 may play a regulatory role either by facilitat-
ing apoptosis choice over cell-cycle arrest for p53 in
response to stresses, or by regulating p53 downstream
targets that are implicated directly in apoptosis, such as
Bax, PUMA and NOXA. Further studies are needed to
prove or disprove these hypotheses. Interestingly, our
previous data showed that NDRG2 also participates in
hypoxia-evoked apoptotic response in A549 cells at least
partially by acting as a hypoxia-inducible HIF-1 target
gene (34), provided that hypoxia-induced p53 accumula-
tion (60) and subsequent induction of NDRG2 may play a
role during this process. Collectively, it appears that
NDRG2 can act as a stress-responsive gene to facilitate
cell death in order to eliminate hazardous cells.
We have also shown that NDRG2 overexpression led to
inhibition of cell proliferation, regardless of the absence or
presence of p53, which is consistent with previous reports
(43,59). These results suggest that Ndrg2 has an inhibitory
role on proliferation that might be p53 independent.
Nevertheless, in case of p53-intact cells, whether the
proliferation-inhibitory role of Ndrg2 inﬂuences its posi-
tive role in apoptosis and vice versa still remains to be
determined.
In summary, this study demonstrated for the ﬁrst time
that NDRG2, a novel p53-inducible gene, is implicated in
the p53-mediated apoptosis pathway in response to DNA
damage and also plays a proliferation-inhibitory role that
is independent of p53 status. These ﬁndings contribute
insights for the function of Ndrg2, particularly its stress-
responsive activity and tumor-repressive eﬀects.
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